Revolution Medicines advisor sells 5,569 shares

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that senior advisor to the CEO Stephen Michael Kelsey sold a total of 5,569 shares of common stock on September 16, 2026, in open-market transactions made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units. One sale of 85 shares reflected a weighted average price between $195.00 and $195.03 per share, and the other sale of 5,484 shares was at $199.30 per share; reported holdings include 65,613 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 5,569 shares

Net Sell 2 txns

Insider Kelsey Stephen Michael

Role See Remarks

Sold 5,569 shs ($1.11M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	85	$195.0074	$17K
Sale	Common Stock F1, F3	5,484	$199.3032	$1.09M

Holdings After Transaction: Common Stock — 286,307 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
2. F2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 65,613 restricted stock units.

Key Figures

Shares sold (total): 5,569 shares First sale shares: 85 shares First sale price range: $195.00–$195.03 per share +4 more

7 metrics

Shares sold (total) 5,569 shares Common stock sales reported for September 16, 2026

First sale shares 85 shares Portion of total shares sold on September 16, 2026

First sale price range $195.00–$195.03 per share Multiple trades with weighted average price for 85-share sale

Second sale shares 5,484 shares Larger open-market sale on September 16, 2026

Second sale price $199.30 per share Reported price per share for 5,484-share sale

Restricted stock units held 65,613 restricted stock units Equity holdings noted as included in reported position

Rule 10b5-1 adoption date May 31, 2023 Adoption date of instruction letter governing these sales

Key Terms

Rule 10b5-1 instruction letter, restricted stock units, weighted average sale price, tax withholding obligation

4 terms

Rule 10b5-1 instruction letter regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted"

restricted stock units financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD report for Stephen Michael Kelsey?

RVMD reported that senior advisor Stephen Michael Kelsey sold 5,569 shares of common stock on September 16, 2026, in open-market transactions made under a Rule 10b5-1 instruction letter to cover tax withholding on vested restricted stock units.

At what prices were the RVMD shares sold by Stephen Michael Kelsey?

Kelsey sold 85 shares at a weighted average price with trades between $195.00 and $195.03 per share, and 5,484 shares at $199.30 per share, all as common stock of Revolution Medicines, Inc.

Was the RVMD insider sale made under a Rule 10b5-1 plan?

Yes. The transactions were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, which was established to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units.

How many RVMD restricted stock units does Stephen Michael Kelsey hold after these transactions?

Reported holdings include 65,613 restricted stock units of Revolution Medicines, Inc. common stock. This figure is part of the reporting person’s equity position and is specifically identified as restricted stock units.

How many RVMD shares did Stephen Michael Kelsey sell in total on September 16, 2026?

On September 16, 2026, Stephen Michael Kelsey sold a total of 5,569 shares of RVMD common stock, consisting of 85 shares in one transaction and 5,484 shares in another transaction.

What is Stephen Michael Kelsey’s role at RVMD mentioned in the Form 4?

Stephen Michael Kelsey is identified as a Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc., as reflected in the remarks section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:04 PM Accepted by SEC EDGAR 09/18/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		85	D	$195.0074(2)	291,791	D
Common Stock	09/16/2026		S(1)		5,484	D	$199.3032	286,307(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 65,613 restricted stock units.

Remarks:

Senior Advisor to the Chief Executive Officer

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)